The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant
Open Access
- 25 February 2004
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 125 (1) , 64-68
- https://doi.org/10.1111/j.1365-2141.2004.04867.x
Abstract
The frequency and prognostic relevance of translocations t(11;14) and t(4;14), the most common translocations involving the immunoglobulin heavy chain (IgH) gene in multiple myeloma (MM), were investigated in 128 patients treated with intensive chemotherapy and autologous stem cell transplant. Myeloma cells were identified by cytoplasmic light chain immunofluorescence combined with fluorescence in situ hybridization (cIg‐FISH) for detection of translocations t(11;14) and t(4;14). Overall, t(11;14) was detected in 16 of 125 (12·8%) and t(4;14) in 15 of 120 (12·5%) patients. Progression‐free and overall survivals were similar for patients with or without t(11;14). However, patients with t(4;14) had significantly shorter progression‐free (median 9·9 months vs. 25·8 months; P = 0·0003) and overall survivals (median 18·3 months vs. 48·1 months; P < 0·0001) than patients without t(4;14). The t(4;14) was associated with IgA and t(11;14) with light chain MM. There was no association between the t(11;14) or t(4;14) and other biological parameters including age, gender, haemoglobin, β‐2 microglobulin, C‐reactive protein, calcium, creatinine, albumin, or the percentage of bone marrow plasma cells. Multivariate analysis identified t(4;14) as the only adverse prognostic factor for both progression‐free survival and overall survival. Our results indicate that the t(4;14) detected by cIg‐FISH is associated with a poor prognosis in MM patients receiving intensive chemotherapy and autotransplant.Keywords
This publication has 26 references indexed in Scilit:
- Clinical and biologic implications of recurrent genomic aberrations in myelomaBlood, 2003
- In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expressionBlood, 2003
- Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapyBlood, 2002
- Chromosome translocations in multiple myelomaOncogene, 2001
- Ectopic Expression of MAFB Gene in Human Myeloma Cells Carrying (14;20)(q32;q11) Chromosomal TranslocationsJapanese Journal of Cancer Research, 2001
- The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cellsBlood, 2001
- Cytogenetics in Multiple Myeloma: A Multicenter Study of 24 Patients with t(11;14)(q13;q32) or Its VariantCancer Genetics and Cytogenetics, 1998
- Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3Nature Genetics, 1997
- Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myelomaProceedings of the National Academy of Sciences, 1996
- Cytogenetic findings in 200 patients with multiple myelomaCancer Genetics and Cytogenetics, 1995